The Potential for Rapid Antigen Testing for Mucormycosis in the Context of COVID-19.
Christopher R ThorntonPublished in: Expert review of molecular diagnostics (2023)
Despite improved recognition, global healthcare systems remain unprepared for further outbreaks of ROCM. Current diagnosis of the disease is slow and inaccurate, negatively impacting on patient survival. This is most evident in low- to middle-income countries which lack suitably equipped diagnostic facilities for rapid identification of the infecting pathogens. Rapid antigen testing using point-of-care lateral-flow assays could potentially have aided in the quick and accurate diagnosis of the disease, allowing earlier intervention with surgery and Mucorales-active antifungal drugs.
Keyphrases
- healthcare
- loop mediated isothermal amplification
- coronavirus disease
- sars cov
- randomized controlled trial
- minimally invasive
- physical activity
- coronary artery bypass
- high resolution
- high throughput
- risk assessment
- gram negative
- coronary artery disease
- mass spectrometry
- multidrug resistant
- antimicrobial resistance
- human health
- health information